Sitaramesh Emani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sitaramesh Emani has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Kilic
Division of Cardiac Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland
3 shared publications Garrie Haas
3 shared publicationsAyesha K. Hasan
Division of Cardiothoracic Surgery, Baylor Scott & White Healthcare, Temple, Texas (Ravi, Sai-Sudhakar); the College of Medicine, The Ohio State University, Columbus, Ohio (Campagna); the Department of Medical Physiology, Texas A&M Health Science Center, Temple, Texas (Rosas); the Division of Cardiology, The Ohio State University, Columbus, Ohio (Essa, Hasan, Emani); and the Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland (Higgins)
2 shared publicationsDonald Kikta
2 shared publicationsJennifer Host
2 shared publicationsJohn Stulak
Division of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota
2 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Evaluating Standard Shielding Versus Novel Enhanced Radiation Protection Devices in the Cardiac Catheterization Laboratory
Background: Enhanced radiation protection devices (ERPDs) have the potential to reduce occupational risks in the cardiac catheterization laboratory. We aimed to investigate scatter radiation exposure to various cardiac catheterization laboratory members using 2 ERPDs. Methods: We prospectively allocated cases to 3 different shielding conditions: standard shielding (group 1), EggNest Protect ERPD (group 2), and EggNest Complete ERPD (group 3). Real‐time dosimetry was used to measure radiation exposure at 3 positions: primary operator (position 1), assistant (position 2), and circulating nurse (position 3). Effective dose equivalent was estimated (annualized to 300 cases/y). Results: A total of 135 patients were included in the study (mean age, 68±11 years; 73% men). For position 1, annualized effective dose equivalent ‐1 doses were 51.4 (19.1–101.3), 7.0 (2.3–21.5), and 2.4 (0.9–6.2) mRem for groups 1, 2, and 3, respectively ( P P P =0.003) standard shielding versus Protect ERPD: 0.3 (−0.4 to 1.2), standard shielding versus Complete ERPD: 0.4 (−0.1 to 1.4). With the use of the EggNest Complete ERPD without a lead apron, annualized total effective doses are ≤1% of the recommended annual maximum for all positions. Conclusions: Compared with standard shielding, ERPDs significantly lowered scatter radiation exposure to all members of the cardiac catheterization laboratory.
- 20 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Open AccessEvaluating Standard Shielding Versus Novel Enhanced Radiation Protection Devices in the Cardiac Catheterization Laboratory
Background: Enhanced radiation protection devices (ERPDs) have the potential to reduce occupational risks in the cardiac catheterization laboratory. We aimed to investigate scatter radiation exposure to various cardiac catheterization laboratory members using 2 ERPDs. Methods: We prospectively allocated cases to 3 different shielding conditions: standard shielding (group 1), EggNest Protect ERPD (group 2), and EggNest Complete ERPD (group 3). Real‐time dosimetry was used to measure radiation exposure at 3 positions: primary operator (position 1), assistant (position 2), and circulating nurse (position 3). Effective dose equivalent was estimated (annualized to 300 cases/y). Results: A total of 135 patients were included in the study (mean age, 68±11 years; 73% men). For position 1, annualized effective dose equivalent ‐1 doses were 51.4 (19.1–101.3), 7.0 (2.3–21.5), and 2.4 (0.9–6.2) mRem for groups 1, 2, and 3, respectively ( P P P =0.003) standard shielding versus Protect ERPD: 0.3 (−0.4 to 1.2), standard shielding versus Complete ERPD: 0.4 (−0.1 to 1.4). With the use of the EggNest Complete ERPD without a lead apron, annualized total effective doses are ≤1% of the recommended annual maximum for all positions. Conclusions: Compared with standard shielding, ERPDs significantly lowered scatter radiation exposure to all members of the cardiac catheterization laboratory.
- Open Access
- 29 September 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
Renovating While in Residence: Constructing a Sustainable Future for Interventional Heart Failure
- 29 September 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
Open AccessRenovating While in Residence: Constructing a Sustainable Future for Interventional Heart Failure
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (1)
Estimating the Placebo Effect on Patient-Reported Outcomes in Sham-Controlled Device Trials: Insights From REDUCE LAP-HF II
BACKGROUND: Patient-reported outcomes are increasingly used as end points in clinical trials. However, the magnitude of observed changes in control arms attributable to placebo effects, as compared with other benefits of trial participation, has not been described. This study seeks to estimate the magnitude of the placebo effect by calculating changes in Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) scores, which quantify the impact of heart failure on patients’ symptoms, function, and quality of life, after participants were unblinded to treatment. METHODS: REDUCE LAP-HF II (Reduce Elevated Left Atrial Pressure in Patients With Heart Failure II) randomized participants to atrial shunt or sham procedure, with unblinding after 2 years. The KCCQ was collected at baseline, 2, and 3 years after randomization. KCCQ-OS change from baseline to 2 years (placebo effect plus other benefits from trial participation) and the change from 2 to 3 years (placebo effect loss after unblinding) were calculated in sham-treated patients using mean±SD, as were changes from 2 to 3 years in shunt-treated patients (placebo effect benefit). RESULTS: The analytic cohort included 421 participants (median age, 72 years; 65.6% female). Among sham-treated participants (N=182), the mean±SD KCCQ-OS 2-year improvement from baseline was +9.3±22.4 points, with a decrement after unblinding of −1.7±18.2 points from 2 to 3 years. Among shunt-treated patients (N=239), mean±SD KCCQ-OS 2-year improvement was +12.7±22.8 points, with an improvement after unblinding of +1.9±18.2 points. In a hypothetical unblinded trial where placebo effect benefit would be expected in the active intervention arm, and none in the untreated arm, the combined effects would be 3.6 points. CONCLUSIONS: In a sham-controlled device trial that collected patient-reported outcome data during blinded allocation to treatment or sham and after unblinding, the estimated mean placebo effect benefit and loss on the KCCQ-OS were small (≤2 points). Finding a modest placebo effect on patient-reported outcomes may increase confidence in their use as clinical trial outcomes.
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (1)
Estimating the Placebo Effect on Patient-Reported Outcomes in Sham-Controlled Device Trials: Insights From REDUCE LAP-HF II
BACKGROUND: Patient-reported outcomes are increasingly used as end points in clinical trials. However, the magnitude of observed changes in control arms attributable to placebo effects, as compared with other benefits of trial participation, has not been described. This study seeks to estimate the magnitude of the placebo effect by calculating changes in Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) scores, which quantify the impact of heart failure on patients’ symptoms, function, and quality of life, after participants were unblinded to treatment. METHODS: REDUCE LAP-HF II (Reduce Elevated Left Atrial Pressure in Patients With Heart Failure II) randomized participants to atrial shunt or sham procedure, with unblinding after 2 years. The KCCQ was collected at baseline, 2, and 3 years after randomization. KCCQ-OS change from baseline to 2 years (placebo effect plus other benefits from trial participation) and the change from 2 to 3 years (placebo effect loss after unblinding) were calculated in sham-treated patients using mean±SD, as were changes from 2 to 3 years in shunt-treated patients (placebo effect benefit). RESULTS: The analytic cohort included 421 participants (median age, 72 years; 65.6% female). Among sham-treated participants (N=182), the mean±SD KCCQ-OS 2-year improvement from baseline was +9.3±22.4 points, with a decrement after unblinding of −1.7±18.2 points from 2 to 3 years. Among shunt-treated patients (N=239), mean±SD KCCQ-OS 2-year improvement was +12.7±22.8 points, with an improvement after unblinding of +1.9±18.2 points. In a hypothetical unblinded trial where placebo effect benefit would be expected in the active intervention arm, and none in the untreated arm, the combined effects would be 3.6 points. CONCLUSIONS: In a sham-controlled device trial that collected patient-reported outcome data during blinded allocation to treatment or sham and after unblinding, the estimated mean placebo effect benefit and loss on the KCCQ-OS were small (≤2 points). Finding a modest placebo effect on patient-reported outcomes may increase confidence in their use as clinical trial outcomes.
- 27 April 2022
- Published by Springer Nature
- p. 33-41
Hemodynamic Assessment of Tricuspid Valve Disease
- 1 October 2020
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 31 (7) , 427-432
Interatrial shunt devices for the treatment of heart failure
- 1 October 2020
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 31 (7) , 427-432
Interatrial shunt devices for the treatment of heart failure
- 1 October 2018
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 28 (7) , 489-490
Editorial commentary: Technology to treat heart failure: Friend or foe?
- 1 October 2018
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 28 (7) , 489-490
Editorial commentary: Technology to treat heart failure: Friend or foe?
- 20 August 2018
- Published by Elsevier in Heart Failure Clinics
- Vol. 14 (4) , 517-524
Ultrafiltration for the Treatment of Acute Heart Failure
- 20 August 2018
- Published by Elsevier in Heart Failure Clinics
- Vol. 14 (4) , 517-524
Ultrafiltration for the Treatment of Acute Heart Failure
- 1 July 2018
- Published by Elsevier in Critical Care Clinics
- Vol. 34 (3) , 465-477
Complications of Durable Left Ventricular Assist Device Therapy
- 1 July 2018
- Published by Elsevier in Critical Care Clinics
- Vol. 34 (3) , 465-477
Complications of Durable Left Ventricular Assist Device Therapy
- 18 February 2017
- Published by Springer Nature in Current Heart Failure Reports
- Vol. 14 (1) , 40-47
Remote Monitoring to Reduce Heart Failure Readmissions
Rehospitalization for heart failure remains a challenge in the treatment of affected patients. The ability to remotely monitor patients for worsening heart failure may provide an avenue through which therapeutic interventions can be made to prevent a rehospitalization. Available data on remote monitoring to reduce heart failure rehospitalizations are reviewed within.
- 18 February 2017
- Published by Springer Nature in Current Heart Failure Reports
- Vol. 14 (1) , 40-47
Remote Monitoring to Reduce Heart Failure Readmissions
Rehospitalization for heart failure remains a challenge in the treatment of affected patients. The ability to remotely monitor patients for worsening heart failure may provide an avenue through which therapeutic interventions can be made to prevent a rehospitalization. Available data on remote monitoring to reduce heart failure rehospitalizations are reviewed within.